Plain-English translation of NCT04804007 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether patients with germ cell cancer who have already completed intensive chemotherapy (called high-dose chemotherapy with stem cell transplant) benefit from taking a daily oral medication called to prevent the cancer from returning. You would be randomly assigned to either take this medication every day for a period of time, or to simply be monitored without additional treatment. The goal is to understand which approach works best at keeping the cancer from coming back.
Germ cell cancer that returns after initial treatment is very serious, and patients who receive intensive chemotherapy still face a risk of the cancer recurring. Doctors want to know whether continuing with this medication after intensive treatment can improve outcomes and prevent relapse, or whether observation alone is sufficient.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to one of two groups: one group takes a 50-milligram oral pill daily, while the other group simply has regular follow-up appointments with monitoring only. Both groups will have periodic blood tests and imaging scans to watch for any signs of cancer returning. The study will track your health and cancer status over time to see which approach is more effective at preventing relapse.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Nabil Adra
Enrollment target
~64 participants
Started
March 2021
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Christin Snow, RN
Indiana University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.